BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vierling JM. Autoimmune Hepatitis and Overlap Syndromes: Diagnosis and Management. Clin Gastroenterol Hepatol. 2015;13:2088-2108. [PMID: 26284592 DOI: 10.1016/j.cgh.2015.08.012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Liu J, Ma Z, Li H, Li X. Chinese medicine in the treatment of autoimmune hepatitis: Progress and future opportunities. Anim Models and Exp Med. [DOI: 10.1002/ame2.12201] [Reference Citation Analysis]
2 Efe C, Ozaslan E, Purnak T. Methotrexate in the Treatment of Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2018;16:149. [PMID: 28844782 DOI: 10.1016/j.cgh.2017.08.029] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
3 Deswal S, Srivastava A. Role of Allopurinol in Optimizing Thiopurine Therapy in Patients with Autoimmune Hepatitis: A Review. J Clin Exp Hepatol 2017;7:55-62. [PMID: 28348471 DOI: 10.1016/j.jceh.2017.01.115] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
4 Yuan X, Duan SZ, Cao J, Gao N, Xu J, Zhang L. Noninvasive inflammatory markers for assessing liver fibrosis stage in autoimmune hepatitis patients. Eur J Gastroenterol Hepatol 2019;31:1467-74. [PMID: 31107735 DOI: 10.1097/MEG.0000000000001437] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
5 Yik B, Shah N. Autoconversion of Autoimmune Liver Diseases. Dig Dis Sci 2020;65:71-3. [PMID: 31451985 DOI: 10.1007/s10620-019-05794-1] [Reference Citation Analysis]
6 Liberal R, Mieli-Vergani G, Vergani D. Contemporary issues and future directions in autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2016;10:1163-74. [PMID: 27215278 DOI: 10.1080/17474124.2016.1193004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 To U, Silveira M. Overlap Syndrome of Autoimmune Hepatitis and Primary Biliary Cholangitis. Clinics in Liver Disease 2018;22:603-11. [DOI: 10.1016/j.cld.2018.03.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Demir N, Ekin N, Torgutalp M, Wahlin S, Efe C. Two decades of research on autoimmune liver disease in Turkey. Turk J Gastroenterol 2020;31:877-82. [PMID: 33626000 DOI: 10.5152/tjg.2020.19866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Liberal R, Krawitt EL, Vierling JM, Manns MP, Mieli-Vergani G, Vergani D. Cutting edge issues in autoimmune hepatitis. J Autoimmun. 2016;75:6-19. [PMID: 27502148 DOI: 10.1016/j.jaut.2016.07.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 9.7] [Reference Citation Analysis]
10 Cropley A, Weltman M. The use of immunosuppression in autoimmune hepatitis: A current literature review. Clin Mol Hepatol 2017;23:22-6. [PMID: 28288505 DOI: 10.3350/cmh.2016.0089] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
11 Liberal R, de Boer YS, Andrade RJ, Bouma G, Dalekos GN, Floreani A, Gleeson D, Hirschfield GM, Invernizzi P, Lenzi M, Lohse AW, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling JM, Heneghan MA; International Autoimmune Hepatitis Group (IAIHG). Expert clinical management of autoimmune hepatitis in the real world. Aliment Pharmacol Ther. 2017;45:723-732. [PMID: 28004405 DOI: 10.1111/apt.13907] [Cited by in Crossref: 49] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
12 Malik N, Venkatesh SK. Imaging of autoimmune hepatitis and overlap syndromes. Abdom Radiol (NY). 2017;42:19-27. [PMID: 27999888 DOI: 10.1007/s00261-016-1019-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
13 Rizvi S, Gawrieh S. Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management. Drugs Aging. 2018;35:589-602. [PMID: 29971609 DOI: 10.1007/s40266-018-0556-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
14 Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol 2020; 26(38): 5896-5910 [PMID: 33132643 DOI: 10.3748/wjg.v26.i38.5896] [Reference Citation Analysis]
15 Purnak T, Efe C, Kav T, Wahlin S, Ozaslan E. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. Dig Dis Sci. 2017;62:2900-2907. [PMID: 28871464 DOI: 10.1007/s10620-017-4728-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
16 Han E, Jo SJ, Lee H, Choi AR, Lim J, Jung ES, Oh EJ. Clinical relevance of combined anti-mitochondrial M2 detection assays for primary biliary cirrhosis. Clin Chim Acta 2017;464:113-7. [PMID: 27864100 DOI: 10.1016/j.cca.2016.11.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
17 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 7.6] [Reference Citation Analysis]
18 Fasano R, Malerba E, Prete M, Solimando AG, Buonavoglia A, Silvestris N, Leone P, Racanelli V. Impact of Antigen Presentation Mechanisms on Immune Response in Autoimmune Hepatitis. Front Immunol 2022;12:814155. [DOI: 10.3389/fimmu.2021.814155] [Reference Citation Analysis]
19 Wu HM, Sheng L, Wang Q, Bao H, Miao Q, Xiao X, Guo CJ, Li H, Ma X, Qiu DK, Hua J. Performance of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis-primary biliary cholangitis overlap syndrome. World J Gastroenterol 2018; 24(6): 737-743 [PMID: 29456412 DOI: 10.3748/wjg.v24.i6.737] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
20 Efe C, Ozaslan E, Purnak T. Second-line immunosuppressants for autoimmune hepatitis. Eur J Gastroenterol Hepatol 2018;30:490-1. [PMID: 29509605 DOI: 10.1097/MEG.0000000000001077] [Reference Citation Analysis]
21 Efe C, Hagström H, Ytting H, Bhanji RA, Müller NF, Wang Q, Purnak T, Muratori L, Werner M, Marschall HU, Muratori P, Gunşar F, Klintman D, Parés A, Heurgué-Berlot A, Schiano TD, Cengiz M, May-Sien Tana M, Ma X, Montano-Loza AJ, Berg T, Verma S, Larsen FS, Ozaslan E, Heneghan MA, Yoshida EM, Wahlin S. Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2017;15:1950-1956.e1. [PMID: 28603052 DOI: 10.1016/j.cgh.2017.06.001] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 10.0] [Reference Citation Analysis]
22 Mieli-Vergani G, Vergani D, Czaja AJ, Manns MP, Krawitt EL, Vierling JM, Lohse AW, Montano-Loza AJ. Autoimmune hepatitis. Nat Rev Dis Primers. 2018;4:18017. [PMID: 29644994 DOI: 10.1038/nrdp.2018.17] [Cited by in Crossref: 92] [Cited by in F6Publishing: 83] [Article Influence: 23.0] [Reference Citation Analysis]
23 Yilmaz B, Unlu O, Evcen R, Ugurluoglu C. Acute onset seronegative autoimmune hepatitis: are simplified diagnostic criteria sufficient? Eur J Gastroenterol Hepatol 2016;28:607-8. [PMID: 27010476 DOI: 10.1097/MEG.0000000000000580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
24 El‐serag HB. Epidemiology of Hepatocellular Carcinoma. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 758-72. [DOI: 10.1002/9781119436812.ch59] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
25 Muratori P, Lenzi M, Cassani F, Lalanne C, Muratori L. Diagnostic approach to autoimmune hepatitis. Expert Rev Clin Immunol 2017;13:769-79. [PMID: 28480763 DOI: 10.1080/1744666X.2017.1327355] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol 2017;112:18-35. [PMID: 27995906 DOI: 10.1038/ajg.2016.517] [Cited by in Crossref: 300] [Cited by in F6Publishing: 244] [Article Influence: 50.0] [Reference Citation Analysis]
27 Jiang Y, Xu BH, Rodgers B, Pyrsopoulos N. Characteristics and Inpatient Outcomes of Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome. J Clin Transl Hepatol 2021;9:392-8. [PMID: 34221925 DOI: 10.14218/JCTH.2021.00008] [Reference Citation Analysis]
28 Androutsakos T, Stamopoulos P, Aroni K, Hatzis G. A case report of successful treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis, and review of the literature. BMC Gastroenterol 2015;15:149. [PMID: 26502871 DOI: 10.1186/s12876-015-0376-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]